Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 Injection in Relapsed or Refractory Autoimmune Cytopenias (Phase I/II)
CTR20253521Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Nov 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AIHA), cold agglutinin disease (CAD), Evans syndrome, sponsored by Keymed Biosciences. Started Nov 2025; status: active.
02
Drugs
gamgertamig
03
Conditions
immune thrombocytopenia (ITP)autoimmune haemolytic anaemia (AIHA)cold agglutinin disease (CAD)Evans syndrome
Beyond the preview
Go deeper on CTR20253521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253521.